Switchable Cas9 nucleases and uses thereof
Some aspects of this disclosure provide compositions, methods, systems, and kits for controlling the activity and/or improving the specificity of RNA-programmable endonucleases, such as Cas9. For example, provided are guide RNAs (gRNAs) that are engineered to exist in an “on” or “off state, which control the binding and hence cleavage activity of RNA-programmable endo-nucleases. Some aspects of this disclosure provide mRNA-sensing gRNAs that modulate the activity of RNA-programmable endo-nucleases based on the presence or absence of a target mRNA. Some aspects of this disclosure provide gRNAs that modulate the activity of an RNA-programmable endonuclease based on the presence or absence of an extended DNA (xDNA).
1. A complex comprising:
(i) a single guide RNA (sgRNA) comprising a sgRNA backbone and an aptamer, wherein the sgRNA does not hybridize to a target nucleic acid in the absence of a specific ligand bound to the aptamer; and
(ii) a Cas9 protein bound to the sgRNA.
2. The complex of claim 1 , wherein the aptamer is bound by the specific ligand.
3. The complex of claim 2 , wherein the specific ligand is a small molecule, a metabolite, a peptide, or a nucleic acid.
4. The complex of claim 3 , wherein the complex binds the target nucleic acid.
5. A single-guide RNA (sgRNA) comprising a sgRNA backbone and an aptamer, wherein the sgRNA does not hybridize to a target nucleic acid in the absence of a specific ligand bound to the aptamer.
6. The sgRNA of claim 5 , wherein the sgRNA does not bind Cas9 in the absence of the specific ligand bound to the aptamer.
7. The sgRNA of claim 5 , wherein the sgRNA binds Cas9 when the specific ligand is bound to the aptamer.
8. The sgRNA of claim 5 , wherein the sgRNA binds Cas9 in the absence or presence of the specific ligand bound to the aptamer.
9. The sgRNA of claim 5 , wherein the specific ligand is a small molecule, a metabolite, a peptide, or a nucleic acid.
10. The sgRNA of claim 5 , wherein the aptamer is an RNA aptamer.
11. The sgRNA of claim 10 , wherein the RNA aptamer is derived from a riboswitch.
12. The sgRNA of claim 11 , wherein the riboswitch is a theophylline riboswitch, a thiamine pyrophosphate (TPP) riboswitch, an adenosine cobalamin (AdoCbl) riboswitch, an S-adenosyl methionine (SAM) riboswitch, an SAH riboswitch, a flavin mononucleotide (FMN) riboswitch, a tetrahydrofolate riboswitch, a lysine riboswitch, a glycine riboswitch, a purine riboswitch, a GlmS riboswitch, or a pre-queosine 1 (PreQ1) riboswitch.
13. A polynucleotide encoding the sgRNA of claim 5 .
14. A method for site-specific nucleic acid cleavage comprising contacting a target nucleic acid with a complex comprising (i) the sgRNA of claim 5 , wherein the sgRNA comprises a sequence that binds to a portion of the target nucleic acid, (ii) a specific ligand bound to the aptamer of the sgRNA, and (iii) a Cas9 protein, under conditions in which the Cas9 protein cleaves the target nucleic acid.
15. A method for inducing site-specific nucleic acid cleavage in a cell comprising:
(a) contacting a cell or expressing within a cell the sgRNA of claim 5 , wherein the sgRNA comprises a sequence capable of binding to a target nucleic acid;
(b) contacting the cell or expressing within the cell a Cas9 protein; and
(c) contacting the cell with the specific ligand that binds the aptamer of the sgRNA, resulting in the formation of a sgRNA:ligand:Cas9 complex that cleaves the target nucleic acid.
16. A method for inducing site-specific nucleic acid cleavage in a cell comprising (a) contacting the cell with a complex comprising a Cas9 protein and the sgRNA of claim 5 , wherein the sgRNA comprises a sequence capable of binding to a target nucleic acid, and (b) contacting the cell with the specific ligand that binds the aptamer of the sgRNA, resulting in the formation of a sgRNA:ligand:Cas9 complex that cleaves the target nucleic acid.
17. The sgRNA of claim 5 , wherein the aptamer is a theophylline riboswitch.
18. The sgRNA of claim 17 , wherein the theophylline riboswitch comprises SEQ ID NO: 3.
19. The sgRNA of claim 17 , wherein the specific ligand is theophylline.
20. The sgRNA of claim 5 , wherein the aptamer is located at a 5′ end of the sgRNA.